We are live on
!
Find out more
LGM
Logos Global Management Portfolio holdings
AUM
$2B
1-Year Est. Return
444.09%
This Fund
S&P 500
This Quarter
Est. Return
+25.15%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$735M
AUM Growth
+$36.5M
(+5.2%)
Cap. Flow
-$61.8M
Cap. Flow
% of AUM
-8.41%
Top 10 Holdings %
Top 10 Hldgs %
51.18%
Holding
61
New
18
Increased
7
Reduced
18
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ACLX
Arcellx
ACLX
|
+$19.1M |
| 2 |
ICVX
Icosavax, Inc. Common Stock
ICVX
|
+$17.3M |
| 3 |
MRSN
Mersana Therapeutics
MRSN
|
+$16.4M |
| 4 |
Annexon
ANNX
|
+$15.3M |
| 5 |
Cytokinetics
CYTK
|
+$14.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IDEAYA Biosciences
IDYA
|
+$38M |
| 2 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$37M |
| 3 |
Xenon Pharmaceuticals
XENE
|
+$24.8M |
| 4 |
Ascendis Pharma A/S
ASND
|
+$16.1M |
| 5 |
APLS
Apellis Pharmaceuticals
APLS
|
+$15.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MOR
26
DELISTED
MorphoSys AG American Depositary Shares
MOR
| $8.96M | 1.22% |
1,200,000
-300,000
| -20% | -$1.83M |
|
27
BioMarin Pharmaceuticals
BMRN
$11.6B
| $8.67M | 1.18% |
100,000
-50,000
| -33% | -$4.71M |
|
|
VTYX
28
DELISTED
Ventyx Biosciences
VTYX
| $8.2M | 1.12% |
250,000
-20,000
| -7% | -$689K |
|
|
DAWN
29
DELISTED
Day One Biopharmaceuticals
DAWN
| $7.76M | 1.06% |
+650,000
| New | +$8.49M |
|
|
KRTX
30
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $7.59M | 1.03% |
35,000
-65,000
| -65% | -$13.9M |
|
31
ALX Oncology
ALXO
$272M
| $7.51M | 1.02% |
1,000,000
-500,000
| -33% | -$3.27M |
|
32
Geron
GERN
$949M
| $7.06M | 0.96% |
2,200,000
-1,350,000
| -38% | -$3.84M |
|
33
Delcath Systems
DCTH
$412M
| $6.87M | 0.93% |
+1,178,787
| New | +$7.39M |
|
|
GRCL
34
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| $6.86M | 0.93% |
+1,800,000
| New | +$5.04M |
|
35
Enliven Therapeutics
ELVN
$3.77B
| $6.27M | 0.85% |
307,076
-94,153
| -23% | -$1.9M |
|
36
Immatics
IMTX
$1.18B
| $5.77M | 0.78% |
+500,000
| New | +$4.67M |
|
|
MRNS
37
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $5.7M | 0.78% |
+525,000
| New | +$4.5M |
|
38
Aclaris Therapeutics
ACRS
$750M
| $5.44M | 0.74% |
+525,000
| New | +$4.75M |
|
39
Kura Oncology
KURA
$901M
| $5.29M | 0.72% |
+500,000
| New | +$5.91M |
|
40
BridgeBio Pharma
BBIO
$16.5B
| $5.16M | 0.7% |
+300,000
| New | +$4.51M |
|
41
Rocket Pharmaceuticals
RCKT
$355M
| $4.97M | 0.68% |
250,000
-650,000
| -72% | -$13.1M |
|
42
Vir Biotechnology
VIR
$1.48B
| $4.91M | 0.67% |
+200,000
| New | +$5.02M |
|
|
ATXS
43
DELISTED
Astria Therapeutics
ATXS
| $4.54M | 0.62% |
544,960
-500,000
| -48% | -$5.77M |
|
44
Tenaya Therapeutics
TNYA
$167M
| $3.52M | 0.48% |
+600,000
| New | +$3.49M |
|
|
DBVT
45
DBV Technologies
DBVT
$823M
| $2.28M | 0.31% |
+120,000
| New | +$2.17M |
|
|
VIGL
46
DELISTED
Vigil Neuroscience
VIGL
| $1.77M | 0.24% |
188,390
| – | – |
|
47
Spyre Therapeutics
SYRE
$8.69B
| $1.42M | 0.19% |
+125,715
| New | +$596K |
|
48
Immunic
IMUX
$188M
| $1.06M | 0.14% |
42,118
| – | – |
|
|
LIAN
49
DELISTED
LianBio American Depositary Shares
LIAN
| $638K | 0.09% |
280,000
| – | – |
|
50
Tyra Biosciences
TYRA
$1.85B
| $543K | 0.07% |
31,872
-55,801
| -64% | -$809K |
|
Similar funds
MYAM
RCM
LBC
C
CAM
BGM
SC
AF
Logos Global Management's Q2 2023 Portfolio in Review
As of Q2 2023, Logos Global Management held 61 positions worth $735M, up 5.2% from $699M the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Logos Global Management withdrew a net $61.8M in Q2 2023, closing 10 positions and reducing 18 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $37M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier.
Against the trend, Logos Global Management opened a new position in Arcellx worth $15.8M.
- Logos Global Management's largest Q2 2023 buy was Arcellx: 500,000 shares worth $15.8M.
- Logos Global Management added most to Cytokinetics in Q2 2023, an estimated $14.8M increase.
- Logos Global Management's biggest Q2 2023 reduction was IDEAYA Biosciences, cutting an estimated $38M.
- Logos Global Management fully exited IVERIC bio, Inc. Common Stock in Q2 2023, selling an estimated $37M.
- Logos Global Management's ten largest holdings make up 51% of its $735M portfolio in Q2 2023.
- Logos Global Management opened 18 new positions and closed 10 in Q2 2023.
- Logos Global Management's portfolio value rose 5.2% quarter-over-quarter to $735M.
Based on Logos Global Management's 13F filing for Q2 2023, filed 14 Aug 2023.